Early Tranexamic Acid and Modulating the Inflammatory Response in Sepsis

Launched by ASSIUT UNIVERSITY · May 27, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called tranexamic acid in patients with sepsis, a serious condition caused by infections that can lead to widespread inflammation in the body. The goal is to see if tranexamic acid can help manage this inflammation and improve outcomes for patients. The study is currently looking for participants aged 18 to 65 who have been diagnosed with sepsis and require admission to an intensive care unit (ICU).

To participate, individuals need to be generally healthy with mild to moderate medical conditions and must meet specific criteria, such as not having severe kidney or liver problems, bleeding disorders, or certain other health issues. If eligible, participants will receive treatment and be monitored closely by the medical team throughout the trial. This research could provide valuable insights into new ways to treat sepsis and improve patient care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults (age 18-65 years) of American society of anesthesiologists (ASA) I-II who will be diagnosed with sepsis by qSOFA ≥2
• • \& needed ICU admission.
• Exclusion Criteria:
• • Chronic renal failure
• • Liver cirrhosis
• • Bleeding disorders or current anticoagulant therapy
• • Pregnancy or breastfeeding
• • Impaired color vision
• • Severe vascular ischemia, history of venous thrombosis \& pulmonary embolism
• • Long term treatment with acetylsalicylic acid or non-steroidal anti-inflammatory drugs not discontinued before ICU admission
• • Allergy to tranexamic acid (TXA)